Changes in the treatment of metastatic prostate cancer-new data and open questions

被引：0
作者：
Albers, P. [1 ,2 ]
Boegemann, M. [3 ]
Machtens, S. [4 ]
Merseburger, A. S. [5 ]
Schostak, M. [6 ]
Steuber, T. [7 ]
Wuelfing, C. [8 ]
De Santis, M. [9 ]
机构：
[1] Heinrich Heine Univ, Univ Klinikum, Klin Urol, Med Fak,Comprehens Canc Ctr, Moorenstr 5, D-40225 Dusseldorf, Germany
[2] Heinrich Heine Univ, Univ Tumorzentrum, Moorenstr 5, D-40225 Dusseldorf, Germany
[3] Univ Klinikum Munster, Klin Urol & Kinderurol, Munster, Germany
[4] Marien Krankenhaus, Klin Urol & Kinderurol, Betriebsstatte, GFO Kliniken Rhein Berg, Bergisch Gladbach, Germany
[5] Univ Klinikum Schleswig Holstein, Klin Urol, Campus Lubeck, Lubeck, Germany
[6] Univ Klinikum Magdeburg, Klin Urol & Kinderurol, Magdeburg, Germany
[7] Univ Klinikum Hamburg Eppendorf, Prostatakrebszentrum, Martini Klin, Hamburg, Germany
[8] Asklepios Klin Altona, Abt Urol, Hamburg, Germany
[9] Charite Univ Med Berlin, Klin Urol, Interdisziplinare Uroonkol, Berlin, Germany
来源：
UROLOGE | 2020年 / 59卷 / 03期
关键词：
Androgen receptor; Prostatic neoplasms; castration-naive; Chemotherapy; Oligometastases; Systemic therapy; ANDROGEN DEPRIVATION THERAPY; INCREASED SURVIVAL; MEN; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; CABAZITAXEL; APALUTAMIDE; ABIRATERONE; PREDNISONE;
D O I：
10.1007/s00120-019-01072-0
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The availability of taxane-based chemotherapy and androgen-receptor-targeted agents (ARTAs) have significantly broadened the therapeutic options for patients with metastatic prostate cancer and may also result in longer patient survival. The therapeutic sequence of ARTAs and taxanes may influence outcome and therefore decisions should be made on an individual basis. This article provides guidance for therapeutic decision-making in daily clinical practice by working out criteria that can be used to support individual therapeutic decisions. The focus is on metastatic castration-naive prostate cancer, oligometastatic disease as well as non-metastatic and metastatic castration-resistant prostate cancer.
引用
收藏
页码：307 / 317
页数：11
相关论文
共 45 条
  • [1] Almeida DVP, 2018, ANN ONCOL, V29, P279
  • [2] Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents
    Angelergues, Antoine
    Efstathiou, Eleni
    Gyftaki, Revekka
    Wysocki, Piotr Jan
    Lainez, Nuria
    Gonzalez, Iria
    Castellano, Daniel E.
    Ozguroglu, Mustafa
    Garcia Carbonero, Iciar
    Flechon, Aude
    Borrega, Pablo
    Guillot, Aline
    Campos Balea, Begona
    Le Moulec, Sylvestre
    Esteban, Emilio
    Munarriz, Javier
    Rubio, Gustavo
    Birtle, Alison J.
    Delanoy, Nicolas
    Bellmunt, Joaquim
    Oudard, Stephane
    [J]. CLINICAL GENITOURINARY CANCER, 2018, 16 (04) : E777 - E784
  • [3] Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).
    Angelergues, Antoine
    Maillet, Denis
    Flechon, Aude
    Ozguroglu, Mustafa
    Mercier, Florence
    Guillot, Aline
    Le Moulec, Sylvestre
    Gravis, Gwenaelle
    Beuzeboc, Philippe
    Massard, Christophe
    Rouge, Thibault De La Motte
    Delanoy, Nicolas
    Elaidi, Reza-Thierry
    Oudard, Stephane
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [4] Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
    Attard, Gerhardt
    Borre, Michael
    Gurney, Howard
    Loriot, Yohann
    Andresen-Daniil, Corina
    Kalleda, Ranjith
    Trinh Pham
    Taplin, Mary-Ellen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (25) : 2639 - +
  • [5] Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial
    Boeve, Liselotte M. S.
    Hulshof, Maarten C. C. M.
    Vis, Andre N.
    Zwinderman, Aeilko H.
    Twisk, Jos W. R.
    Witjes, Wim P. J.
    Delaere, Karl P. J.
    van Moorselaar, R. Jeroen A.
    Verhagen, Paul C. M. S.
    van Andel, George
    [J]. EUROPEAN UROLOGY, 2019, 75 (03) : 410 - 418
  • [6] Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.
    Caffo, Orazio
    Bria, Emilio
    De Giorgi, Ugo
    Tucci, Marcello
    Galli, Luca
    Fratino, Lucia
    Rossetti, Sabrina
    Iacovelli, Roberto
    Lo Re, Giovanni
    Mosillo, Claudia
    Gasparro, Donatello
    Guglielmini, Pamela Francesca
    Damiani, Azzurra
    Procopio, Giuseppe
    De Lisi, Delia
    Ruatta, Fiorella
    Scagliarini, Sarah
    Donini, Maddalena
    Sperduti, Isabella
    Basso, Umberto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA)
    Carles, Joan
    Pichler, Angelika
    Korunkova, Hana
    Tomova, Antoaneta
    Ghosn, Marwan
    El Karak, Fadi
    Makdessi, Joseph
    Koroleva, Irina
    Barnes, Gisoo
    Bury, Denise
    Ozatilgan, Ayse
    Hitier, Simon
    Katolicka, Jana
    [J]. BJU INTERNATIONAL, 2019, 123 (03) : 456 - 464
  • [8] Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study
    Culp, Stephen H.
    Schellhammer, Paul F.
    Williams, Michael B.
    [J]. EUROPEAN UROLOGY, 2014, 65 (06) : 1058 - 1066
  • [9] Abiraterone and Increased Survival in Metastatic Prostate Cancer
    De Bono, Johann S.
    Logothetis, Christopher J.
    Molina, Arturo
    Fizazi, Karim
    North, Scott
    Chu, Luis
    Chi, Kim N.
    Jones, Robert J.
    Goodman, Oscar B., Jr.
    Saad, Fred
    Staffurth, John N.
    Mainwaring, Paul
    Harland, Stephen
    Flaig, Thomas W.
    Hutson, Thomas E.
    Cheng, Tina
    Patterson, Helen
    Hainsworth, John D.
    Ryan, Charles J.
    Sternberg, Cora N.
    Ellard, Susan L.
    Flechon, Aude
    Saleh, Mansoor
    Scholz, Mark
    Efstathiou, Eleni
    Zivi, Andrea
    Bianchini, Diletta
    Loriot, Yohann
    Chieffo, Nicole
    Thian Kheoh
    Haqq, Christopher M.
    Scher, Howard I.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) : 1995 - 2005
  • [10] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    de Bono, Johann Sebastian
    Oudard, Stephane
    Ozguroglu, Mustafa
    Hansen, Steinbjorn
    Machiels, Jean-Pascal
    Kocak, Ivo
    Gravis, Gwenaelle
    Bodrogi, Istvan
    Mackenzie, Mary J.
    Shen, Liji
    Roessner, Martin
    Gupta, Sunil
    Sartor, A. Oliver
    [J]. LANCET, 2010, 376 (9747) : 1147 - 1154
12345